Rocklatan Retinal Perfusion OCT Study

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Glaucoma
Interventions
DRUG

Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.

The eye not selected as the study eye will be used for comparison so both eyes will be imaged with the study devices to assess blood flow changes.

DEVICE

Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.

One OCT device is FDA-cleared while the other is still experimental. Both devices assess blood flow in different ways.

Trial Locations (1)

97239

Casey Eye Institute - Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alcon Research

INDUSTRY

lead

Oregon Health and Science University

OTHER